Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum

Clinical and Vaccine Immunology

Volumn 15, Issue 9, 2008, Pages 1345-1355

  Arnot, David E ^a,b   Cavanagh, David R ^b   Remarque, Edmond J ^c   Creasey, Alison M ^b   Sowa, Mercy P K ^a   Morgan, William D ^d   Holder, Anthony A ^d   Longacre, Shirley ^e   Thomas, Alan W ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; APICAL MEMBRANE ANTIGEN 1; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MONTANIDE ISA 720; PLASMODIUM FALCIPARUM ANTIGEN; RECOMBINANT ANTIGEN; RECOMBINANT BACULOVIRUS MEROZOITE SURFACE PROTEIN 1 19; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACULOVIRUS; CONTROLLED STUDY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE FUSION; GROWTH INHIBITION; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; LACTATE DEHYDROGENASE ASSAY; MEROZOITE; MICROSCOPY; NONHUMAN; PICHIA PASTORIS; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN DOMAIN; RABBIT; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BACULOVIRIDAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNOGLOBULIN G; MALARIA; MALARIA VACCINES; MANNITOL; MICROBIAL VIABILITY; OLEIC ACIDS; PICHIA; PLASMODIUM FALCIPARUM; RABBITS; VACCINES, SYNTHETIC;

EID: 51649093813     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00172-08     Document Type: Article

References (24)

1. Arnot, D. E., and K. Gull. 1998. The Plasmodium cell-cycle: facts and questions. Ann. Trop. Med. Parasitol. 92:361-365.
2. Bergmann-Leitner, E. S., E. H. Duncan, G. E. Mullen, J. R. Burge, F. Khan, C. A. Long, E. Angov, and J. A. Lyon. 2006. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood-stage antigens. Am. J. Trop. Med. Hyg. 75:437-442.
3. Bonnet, S., S. Petres, I. Holm, T. Fontaine, S. Rosario, C. Roth, and S. Longacre. 2006. Soluble and glycolipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate. Vaccine 24:5997-6008.
4. Bradford, M. M. 1976. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-252.
5. Carlin, J. M., J. B. Jensen, and T. G. Geary. 1985. Comparison of inducers of crisis forms in Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 34:668-674.
6. Dodoo, D., T. G. Theander, J. A. Kurtzhals, K. Koram, E. Riley, B. D. Akanmori, F. K. Nkrumah, and L. Hviid. 1999. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect. Immun. 67:2131-2137.
7. Egan, A. F., J. Morris, G. Barnish, S. Allen, B. M. Greenwood, D. C. Kaslow, A. A. Holder, and E. M. Riley. 1996. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J. Infect. Dis. 173:765-769.
8. Faber, B. W., E. J. Remarque, W. D. Morgan, C. H. M. Kocken, A. A. Holder, and A. W. Thomas. 2007. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infect. Immun. 75:5947-5955.
9. Hensmann, M., C. Li, C. Moss, V. Lindo, F. Greer, C. Watts, S. A. Ogun, A. A. Holder, and J. Langhorne. 2004. Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response. Eur. J. Immunol. 34:639-648.
10. Hilleman, M. R. 1998. A simplified vaccinologists' vaccinology and the pursuit of a vaccine against AIDS. Vaccine 16:778-793.
11. Holder, A. A., M. J. Lockyer, K. G. Odink, J. S. Sandhu, V. Riveros-Moreno, S. C. Nicholls, Y. Hillman, L. S. Davey, M. L. Tizard, R. T. Schwarz, et al. 1985. Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. Nature 317:270-273.
12. Kennedy, M. C., J. Wang, Y. Zhang, A. P. Miles, F. Chitsaz, A. Saul, C. A. Long, L. H. Miller, and A. W. Stowers. 2002. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 70:6948-6960.
13. Kocken, C. H., C. Withers-Martinez, M. A. Dubbeld, A. van der Wel, F. Hackett, M. J. Blackman, and A. W. Thomas. 2002. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect. Immun. 70:4471-4476.
14. Malaria Vaccine Technology. 2006. Malaria vaccine technology roadmap. Roadmap Working Group. http://www.MalariaVaccineRoadmap.net.
15. Mengiardi, B., R. Berger, M. Just, and R. Gluck. 1995. Virosomes as carriers for combined vaccines. Vaccine 13:1306-1315.
16. Moran, M. G. J., A. Ropars, M. Jorgensen, A. McDonald, S. Potter, and H. Haile-Selassie. 2007. The malaria product pipeline: planning for the future. The George Institute for International Health, Sydney. Australia. http://www.thegeorgeinstitute.org.au.
17. Parra, M., G. Hui, A. H. Johnson, J. A. Berzofsky, T. Roberts, I. A. Quakyi, and D. W. Taylor. 2000. Characterization of conserved T- and B-cell epitopes in Plasmodium falciparum major merozoite surface protein 1. Infect. Immun. 68:2685-2691.
18. Persson, K. E. M., C. T. Lee, K. Marsh, and J. G. Beeson. 2006. Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J. Clin. Microbiol. 44:1665-1673.
19. Polley, S. D., T. Mwangi, C. H. M. Kocken, A. W. Thomas, S. Dutta, D. E. Lanar, E. Remarque, A. Ross, T. N. Williams, G. Mwambingu, B. Lowe, D. J. Conway, and K. Marsh. 2004. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23:718-728.
20. Quakyi, I. A., J. Currier, A. Fell, D. W. Taylor, T. Roberts, R. A. Houghten, R. D. England, J. A. Berzofsky, L. H. Miller, and M. F. Good. 1994. Analysis of human T-cell clones specific for conserved peptide sequences within malaria proteins. Paucity of clones responsive to intact parasites. J. Immunol. 153:2082-2092.
21. Reed, Z. H., M. Friede, and M. P. Kieny. 2006. Malaria vaccine development: progress and challenges. Curr. Mol. Med. 6:231-245.
22. Sedegah, M., Y. Charoenvit, L. Minh, M. Belmonte, V. F. Majam, S. Abot, H. Ganeshan, S. Kumar, D. J. Bacon, A. Stowers, D. L. Narum, D. J. Carucci, and W. O. Rogers. 2004. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther. 11:448-456.
23. Targett, G. A. 2005. Malaria vaccines 1985-2005: a full circle? Trends Parasitol. 21:499-503.
24. Uthaipibull, C., B. Aufiero, S. E. H. Syed, B. Hansen, J. A. Guevara Patino, E. Angov, I. T. Ling, K. Fegeding, W. D. Morgan, C. Ockenhouse, B. Birdsall, J. Feeney, J. A. Lyon, and A. A. Holder. 2001. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 307:1381-1394.